PA
Paul Arndt, MBA
Contact for Institutional Investors and Media at LifeSci Advisors, LLC (Investor Relations Firm)
Palatin TechnologiesTherapeutic Areas
Palatin Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PL9643 (Melody-1) | Dry Eye Disease | Phase 3 |
| PL9643 | Non-Infectious Anterior Uveitis | Phase 2 |
| PL8177 | Inflammatory Bowel Disease / Ulcerative Colitis | Preclinical / Phase 1 |
| PL7737 | Obesity | Preclinical |
| VYLEESI (bremelanotide injection) | Hypoactive Sexual Desire Disorder (HSDD) | Approved |
| Unnamed Melanocortin Program | Retinal Diseases (e.g., Geographic Atrophy) | Discovery |